Lipocine Inc
LPCN
Get informed when a big investor buys or sells
+ FollowMarket Cap$17.89M
Close$
$0.83
64% downside
Current Fair Value
64% downsideOvervalued by 64% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $17.89 Million |
|---|---|
| Enterprise Value | $13.23 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.77 |
| Beta | 0.46 |
| Outstanding Shares | 8,216,988 |
Return
| Return on Equity | -54.45% |
|---|---|
| Return on Assets | -49.72% |
| Return on Invested Capital | 24.04% |
Valuation & Multiples
| P/E Ratio | -1.16 |
|---|---|
| PEG | -6.14 |
| Price to Sales | - |
| Price to Book Ratio | 1.15 |
| Enterprise Value to Revenue | 8.43 |
| Enterprise Value to EBIT | 2.53 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.44
Average shareholder expectationRevenue Estimate
$162,500
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.32
Average shareholder expectationRevenue Estimate
$219,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 45.89%▲ 15.98% |
|---|---|
| Total Invested | $24.92M▲ 90.36% |
| Investors Holding | 46▲ 20.00% |
ESG Score
No data
About Lipocine Inc
CEO: Mahesh Patel Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes: TLANDO, LPCN 1144, TLANDO XR, L...